Terms of the sale of Amplion’s assets to Arlington, Va.-based SMG were not disclosed Wednesday.
“SMG approached Amplion as we were scouting for high quality assets that could help us to build the premier data intelligence company and provide insights about hard-to-reach audiences in life sciences and healthcare,” Ed Burnham, head of market research and analytics at SMG, told GeekWire. Burnham is now leading the Amplion business at SMG.
Amplion’s software sifts through company information and public databases like PubMed.gov and ClinicalTrials.gov for data that can be used by commercial customers to support sales, marketing and business development. It also sells BiomarkerBase, which pulls out information on biomarkers, molecules that indicate diseases and other biological states, such as which ones are associated with clinical trials.
BiomarkerBase is no longer actively marketed, Burnham told GeekWire, but SMG will continue to sell it as part of its portfolio of life science products. SMG provides market research services and publishes sites like DrBicuspid for dental professionals and LabPulse, for experts in lab software, molecular diagnostics, and other fields. SMG has more than 120 employees.
Amplion CEO Chris Capdevila will remain as a consultant and Amplion’s nine employees and contractors will also stay on, said Burnham. Amplion previously raised an undisclosed amount in a Series A funding round and won $400,000 as part of a competition at Bend Venture Conference.
“Science and Medicine Group’s customers now have access to a purpose-built, machine learning platform for life science commercial teams, while Amplion’s customers are assured of continued support and long-term investment from a well-established company to further enhance the platform’s capabilities,” Burnham said in a statement announcing the deal.